GGrantIndex
Sort

82,697 grants matching vaccine development

NIDA Clinical Trials Network: Greater New York Node

$871,690
John P Rotrosen · New York University School Of Medicine · UG1 · FY2015 · DA

Discovery of Molecules to disrupt the outer membrane of Gram-negative pathogens

$871,618
Daniel E Kahne · Harvard Medical School · U19 · FY2014 · AI

Vaccine and Treatment Evaluation Units (VTEU)

$871,600
Hana M El Sahli · Baylor College Of Medicine · UM1 · FY2022 · AI

Animal Core

$871,476
David S Perlin · Columbia University Health Sciences · U54 · FY2010 · AI

Transcutaneous Immunization for Tetanus Booster

$871,356
Iomai Corporation · R44 · FY2002 · AI

SOUTHERN AFRICA-NEW YORK HIV VACCINE TRIALS UNIT

$871,348
Medical Research Council Of South Africa · U01 · FY2004 · AI

Integrated Multi-omics of Melioidosis

$871,221
Timothy Eoin West · University Of Washington · R01 · FY2019 · AI

TOWARDS A MORE RELEVANT MODEL OF HIV INFECTION

$871,200
Julie M Overbaugh · Fred Hutchinson Cancer Research Center · DP1 · FY2016 · DA

Novel Concepts for the Eradication of HIV

$871,184
Rafick-Pierre Sekaly · Vgti Florida · DP1 · FY2013 · DA

Human EGFRvIII-specific BiTE for the treatment of Glioblastoma

$871,073
John H Sampson · Duke University · U01 · FY2019 · NS

Project 1: Development of Nucleoside-Modified mRNAs Encoding Sequential HIV-1 Envelopes for Initiation of V3-glycan Neutralizing Antibody Lineages

$871,042
Barton F Haynes · Duke University · U19 · FY2020 · AI

The Evaluation of Novel Therapeutics for Genitourinary Malignancies

$871,023
William Laurence Dahut · Division Of Clinical Sciences - Nci · ZIA · FY2017 · CA

Alphavirus Vaccines for Biodefense

$870,993
Scott C Weaver · University Of Texas Med Br Galveston · U54 · FY2010 · AI

Molecular analysis of the mucosal SIVsmm transmission bottleneck

$870,987
George M Shaw · University Of Pennsylvania · P01 · FY2014 · AI

Modulation of Viral Antigen Presentation in the Lung

$870,979
Anna Karolina Palucka · Jackson Laboratory · U19 · FY2023 · AI

An OpenData Portal to share SARS-CoV-2 drug repurposing data in real time

$870,948
Matthew Hall · National Center For Advancing Translational Sciences · ZIA · FY2024 · TR

Improving the pharmacokinetics, potency, and immunogenicity of eCD4-Ig

$870,946
Michael David Alpert · Emmune, Inc · R44 · FY2021 · AI

A Tetravalent Dengue Vaccine Based on Alphavirus Replicons

$870,945
Laura J White · Univ Of North Carolina Chapel Hill · U01 · FY2009 · AI

Safety and efficacy of PfSPZ malaria vaccine in malaria-exposed adults

$870,936
Christopher V. Plowe · University Of Maryland Baltimore · U01 · FY2017 · AI

Development of tissue explant models for microbicide evaluation

$870,770
Thomas Hope · Northwestern University At Chicago · R33 · FY2010 · AI

A multi-tiered approach to develop validated assays to predict efficacy of a tetravalent live attenuated Dengue Virus vaccine in Phase II and Phase III clinical trials

$870,724
Rafick-Pierre Sekaly · Case Western Reserve University · R01 · FY2019 · AI

Once Bitten: Acquisition of Malaria Adaptive Immunity (OBAMA - Immunity)

$870,556
Wendy Prudhommeomeara · Duke University · R01 · FY2023 · AI

Dissecting Polyclonal Sera to Reveal Correlates of Productive Immune Responses to HIV

$870,554
Andrew Barrett Ward · Scripps Research Institute, The · R01 · FY2023 · AI

Function of granulysin

$870,505
Alan Krensky · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA

Immunoprevention and immunosurveillance of human non-viral cancers

$870,445
Olivera J Finn · University Of Pittsburgh At Pittsburgh · R35 · FY2019 · CA